TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Kalbe Farma sets up new joint venture

Publicly-listed pharmaceutical company PT Kalbe Farma said it had signed an agreement on June 28 with milk-based beverage producer PT Milko Beverage Industry regarding the establishment of a joint venture called PT Kalbe Milko Indonesia

The Jakarta Post
Wed, July 4, 2012 Published on Jul. 4, 2012 Published on 2012-07-04T08:57:22+07:00

Change text size

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!

P

ublicly-listed pharmaceutical company PT Kalbe Farma said it had signed an agreement on June 28 with milk-based beverage producer PT Milko Beverage Industry regarding the establishment of a joint venture called PT Kalbe Milko Indonesia. Under the agreement, Kalbe will have a 51-percent stake in the joint venture while Milko beverage will own the remaining 49 percent.

“Milko Beverage will run a healthy food and beverage manufacture business,” Kalbe director and corporate secretary Vidjongitus said in a written statement.

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.

Share options

Quickly share this news with your network—keep everyone informed with just a single click!

Change text size options

Customize your reading experience by adjusting the text size to small, medium, or large—find what’s most comfortable for you.

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!

Continue in the app

Get the best experience—faster access, exclusive features, and a seamless way to stay updated.